Clinical Trial Update: FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD [Phase 1, Phase 2]

View source ↗

Summary

The FOCUS study (GT005) in dry age-related macular degeneration was terminated in Phase 1/2, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Dry Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• GT005

Snippet

Sponsor: Gyroscope Therapeutics Limited | Conditions: Dry Age-related Macular Degeneration, Macular Degeneration | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-08-24